Senior Research Officer and Group leader, Diabetes and Transcription Factors, Garvan Institute of Medical Research, Sydney (JDRF/NHMRC fellow); Staff Specialist, Diabetes & Endocrinology, Westmead Hospital; Associate Professor, UNSW, University of Sydney. Held post-doctoral fellowship, Joslin Diabetes Center and Harvard Medical School; PhD, University of Sydney; FRACP (endocrinology & diabetes); MBBS. President of Australian Diabetes Society.

Mathematician expert in machine intelligence, game theory, control of complex systems. Honorary Senior Fellow at the University of Queensland (2011-13). Australia's Spitfire Memorial Defence Fellow, (2005 & 2007). Founder, NeuroTech Research and Diabetes Neuromathix; inventor of patents. Former government senior analyst, experienced in running research projects in public and private sectors.

Michael is a graduate of the University of Melbourne and University of Adelaide (PhD Biochemistry 1992). In 2001 he became the Chief Scientific Officer of Sympore GmbH based in Germany. In 2004 he founded Synovo GmbH, a preclinical services and drug discovery company. In 2005 he founded Hi-Cap Formulations Ltd to develop IP in controlled release formulations. Both companies are profitable and have licensed IP to multi-national enterprise.

Janelle has extensive experience within the banking industry, gained both in Australia and the United Kingdom. She spent several years with UBS and Credit Suisse in the London offices as a Credit Officer assessing M&A transactions as well as highly leveraged and structured transactions. She holds an MBA from the University of Hull in the United Kingdom and a Bachelor of Business degree from Queensland University of Technology.

Jim qualified in medicine and surgery from Charing Cross Hospital, London. In 1986 he co-founded, with Harry Stratford, Shire Pharmaceuticals Ltd. At Shire he supervised UK development of the first licensed treatment for Alzheimer’s, tacrine, followed by galantamine (Reminyl) and Fosrenol. Shire became UK's third largest pharma company (2007 revenue $US 2,436 million). He left Shire in 1999 to set up Hunter-Fleming, acquired in 2008 by Newron.

Barbara has been the primary “angel” investor in NeuroTech Research Pty Ltd, the affiliated R&D company that developed the basic Neuromathix platform technology. She has considerable organisational experience as vice-chairman or chairman of various councils and committees in one of Australia’s two main political parties, including being a long-time Branch Chairman.

John is a constitutional, military and commercial lawyer (he has appeared before the Privy Council in London and Australia’s High Court, been counsel for the Australian Tax Office and lectured in Commercial Law at the University of Queensland). A former parliamentarian and Cabinet Minister, and a former colonel and Reviewing Judge Advocate in the Australian Army Legal Corps, he is experienced in public administration and governance.